Trial · NCT07891429
Registered outcomes23
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 23
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Longitudinal cognitive function _ Clinical Dementia Rating | through study completion, an average of 1 year | Clinical Dementia Rating (CDR). The CDR is used to assess cognitive and functional performance. Scores range from 0 to 3, where 0 indicates no dementia, 0.5 indicates questionable dementia, and higher scores (1, 2, 3) indicate mild, moderate, and severe dementia, respectively. Higher scores indicate a worse outcome. |
| Primary | Longitudinal changes of cognitive function _ Montreal Cognitive Assessment Basic | through study completion, an average of 1 year | Montreal Cognitive Assessment Basic (MoCA-Basic). The MoCA-Basic is a cognitive screening tool with a total score ranging from 0 to 30. Higher scores indicate better cognitive function, while lower scores indicate a worse outcome. |
| Primary | Longitudinal changes of cognitive function _ Mini-mental State Examination, the Chinese version | through study completion, an average of 1 year | Mini-mental State Examination (MMSE, Chinese version). The MMSE is a 30-point questionnaire used to assess cognitive impairment. Scores range from 0 to 30. Higher scores indicate better cognitive function, while lower scores indicate a worse outcome (more severe cognitive impairment). |
| Primary | Longitudinal changes of cognitive function _ Alzheimer's Disease Assessment Scale - Cognitive Subscale | through study completion, an average of 1 year | Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog). The ADAS-Cog is a 70-point scale used to assess cognitive function in Alzheimer's disease. Scores range from 0 to 70. Higher scores indicate a worse outcome (more severe cognitive impairment). |
| Primary | Longitudinal functional and behavioral function _ Neuropsychiatric Inventory | through study completion, an average of 1 year | Neuropsychiatric Inventory (NPI). The NPI is a 144-point scale used to assess neuropsychiatric symptoms in patients with dementia. Scores range from 0 to 144. Higher scores indicate a worse outcome (more severe neuropsychiatric symptoms). |
| Primary | Longitudinal functional and behavioral function _ Geriatric Depression Scale | through study completion, an average of 1 year | Geriatric Depression Scale (GDS-15). The GDS-15 is a 15-item scale used to assess depression in older adults. Scores range from 0 to 15. Higher scores indicate a worse outcome (more severe depressive symptoms). |
| Primary | Longitudinal functional and behavioral function _ Function Activities Questionnaire | through study completion, an average of 1 year | Function Activities Questionnaire (FAQ). The FAQ is a 30-point scale used to assess functional activities in older adults. Scores range from 0 to 30. Higher scores indicate a worse outcome (greater functional impairment/dependency). |
| Primary | Longitudinal functional and behavioral function _Activity of Daily Living Scale | through study completion, an average of 1 year | Activity of Daily Living Scale (ADL). The ADL scale is a 20-item instrument used to assess functional independence in daily living activities, including both basic ADL and instrumental ADL (IADL). Scores range from 20 to 80. Lower scores indicate a better outcome (greater independence), while higher scores indicate a worse outcome (greater dependency). |
| Primary | Longitudinal functional and behavioral function _Pittsburgh Sleep Quality Index | through study completion, an average of 1 year | Pittsburgh Sleep Quality Index (PSQI). The PSQI is a 21-point scale used to assess sleep quality and disturbances over a 1-month interval. Scores range from 0 to 21. Higher scores indicate a worse outcome (poorer sleep quality). |
| Primary | Longitudinal functional and behavioral function _ REM Sleep Behavior Disorder Screening Questionnaire | through study completion, an average of 1 year | REM Sleep Behavior Disorder Screening Questionnaire (RBDSQ). The RBDSQ is a 13-point self-rating questionnaire used to screen for REM sleep behavior disorder. Scores range from 0 to 13, with higher scores indicating a worse outcome (greater likelihood of RBD). |
| Secondary | Longitudinal changes of plasma biomarkers | through study completion, an average of 1 year | Longitudinal changes of disease status as categorized by plasma biomarkers of Alzheimer's diseases over time. |
| Secondary | Longitudinal changes of cerebrospinal fluid biomarkers | through study completion, an average of 1 year | Longitudinal changes of disease status as categorized by cerebrospinal fluid (CSF) biomarkers of Alzheimer's diseases over time. |
| Secondary | Longitudinal changes in neuroimaging _ Magnetic Resonance Imaging | through study completion, an average of 1 year | Longitudinal change in brain structure using magnetic resonance imaging (MRI) |
| Secondary | Longitudinal changes in neuroimaging _ Amyloid PET images | through study completion, an average of 1 year | Longitudinal changes in amyloid deposition |
| Secondary | Longitudinal changes in neuroimaging _ Tau PET images | through study completion, an average of 1 year | Longitudinal changes in tau deposition |
| Secondary | Longitudinal changes in Electroencephalogram Features | through study completion, an average of 1 year | Longitudinal Changes in AD-Related Electroencephalogram (EEG) Features |
| Secondary | Longitudinal changes in digital cognitive phenotype | through study completion, an average of 1 year | Based on multimodal data including eye tracking (fixation duration, saccadic velocity, pupillary response), behavioral responses (reaction time, accuracy, task completion patterns), and spatial navigation (path efficiency, spatial memory error), construct a digital cognitive phenotype of AD and investigate the longitudinal changes in the digital cognitive phenotype. |
| Other | Correlation of the Evolutionary Patterns of AD Pathological Features | through study completion, an average of 1 year | To explore the associations between parameters such as genetic factors, environmental factors, neuroimmune factors, and cerebrovascular factors and plasma markers as well as the aggregation of Aβ plaques and tau tangles in the cerebral cortex. |
| Other | Correlation of AD Risk Genes and Their Mechanisms of Action | through study completion, an average of 1 year | To investigate the relationships between genetic susceptibility genes and AD pathological features and disease evolution. |
| Other | Distribution and Carrier Status of AD Genetic Susceptibility Genes and Risk Loci | Baseline | To observe the distribution and carrier status of AD genetic susceptibility genes and risk loci. Carrier status will be reported as positive or negative for specific risk alleles (e.g., APOE4). |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07891429/registered